Nonclinical evaluation of the serum pharmacodynamic biomarkers HGF and shed MET following dosing with the anti-MET monovalent monoclonal antibody onartuzumab

Molecular Cancer Therapeutics

Volumn 13, Issue 2, 2014, Pages 540-552

  Mai, Elaine ^a   Zheng, Zhong ^b   Chen, Youjun ^b   Peng, Jing ^b   Severin, Christophe ^b   Filvaroff, Ellen ^b   Romero, Mally ^b   Mallet, William ^b   Kaur, Surinder ^c   Gelzleichter, Thomas ^c   Nijem, Ihsan ^a   Merchant, Mark ^b   Young, Judy C ^a,d  

^a GENENTECH INC   (United States)

^b Translational Oncology ^*  (United States)

^c Genentech   (United States)

^d CELGENE CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; MONOCLONAL ANTIBODY; ONARTUZUMAB; SCATTER FACTOR; SCATTER FACTOR RECEPTOR;

ANIMAL; BLOOD; C3H MOUSE; DOSE RESPONSE; DRUG SCREENING; ENDOCYTOSIS; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GENETICS; HELA CELL LINE; HUMAN; IMMUNOASSAY; IMMUNOLOGY; MACACA FASCICULARIS; METABOLISM; NEOPLASMS; NUDE MOUSE; PATHOLOGY; PROCEDURES; RNA INTERFERENCE; SCID MOUSE; TRANSGENIC MOUSE; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOCYTOSIS; FLOW CYTOMETRY; HELA CELLS; HEPATOCYTE GROWTH FACTOR; HUMANS; IMMUNOASSAY; MACACA FASCICULARIS; MICE, INBRED C3H; MICE, NUDE; MICE, SCID; MICE, TRANSGENIC; MICROSCOPY, FLUORESCENCE; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MET; RNA INTERFERENCE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84894208992     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0494     Document Type: Article

References (50)

1. Gherardi E,Birchmeier W,Birchmeier C,VandeWoudeG. TargetingMET in cancer: rationale and progress. Nat Rev Cancer 2012;12:89-103.
2. Peschard P, Park M. From Tpr-MET to MET, tumorigenesis and tubes. Oncogene 2007;26:1276-85.
3. Weidner KM, Sachs M, Riethmacher D, Birchmeier W. Mutation of juxtamembrane tyrosine residue 1001 suppresses loss-of-function mutations of the met receptor in epithelial cells. Proc Natl Acad Sci USA 1995;92:2597-601.
4. Peschard P, Fournier TM, Lamorte L, Naujokas MA, Band H, Langdon WY, et al. Mutation of the c-Cbl TKB domain binding site on the MET receptor tyrosine kinase converts it into a transforming protein. Mol Cell 2001;8:995-1004.
5. Petrelli A, Gilestro GF, Lanzardo S, Comoglio PM, Migone N, Giordano S. The endophilin-CIN85-Cbl complex mediates ligand-dependent downregulation of c-MET. Nature 2002;416:187-90.
6. Peschard P, Ishiyama N, Lin T, Lipkowitz S, Park M. AconservedDpYR motif in the juxtamembrane domain of the MET receptor family forms an atypical c-Cbl/Cbl-b tyrosine kinase binding domain binding site required for suppression of oncogenic activation. J Biol Chem 2004; 279:29565-71.
7. Mazzone M, Comoglio PM. The MET pathway: master switch and drug target in cancer progression. FASEB J 2006;20:1611-21.
8. Tulasne D, Foveau B. The shadow of death on the MET tyrosine kinase receptor. Cell Death Diff 2008;15:427-34.
9. Ferracini R, Di Renzo MF, Scotlandi K, Baldini N, Olivero M, Lollini P, et al. The MET/HGF receptor is over-expressed in human osteosarcomas and is activated by either a paracrine or an autocrine circuit. Oncogene 1995;10:739-49.
10. Kim CH, Moon SK, Bae JH, Lee JH, Han JH, Kim K, et al. Expression of hepatocyte growth factor and c-MET in hypopharyngeal squamous cell carcinoma. Acta Oto-Laryng 2006;126:88-94.
11. Hu B, Guo P, Bar-Joseph I, Imanishi Y, Jarzynka MJ, Bogler O, et al. Neuropilin-1 promotes human glioma progression through potentiating the activity of the HGF/SF autocrine pathway. Oncogene 2007;26: 5577-86.
12. Xie Q, Bradley R, Kang L, Koeman J, Ascierto ML, Worschech A, et al. Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma. Proc Natl Acad Sci USA 2012;109:570-5.
13. Catenacci DVT, Henderson L, Xiao SY, Penuel E, Patel P, Yauch RL, et al. Durable complete response of metastatic gastric cancer with anti-MET therapy followed by resistance at recurrence. Cancer Discov 2011;1:573-9.
14. Eichbaum MHR, de Rossi TM, Kaul S, Bruckner T, Schneeweiss A, Sohn C. Serum levels of hepatocyte growth factor/scatter factor in patients with liver metastases from breast cancer. Tumor Biol 2007;28: 36-44.
15. Guro A, Lian AM, Tingulstad S, Torp SH, Forsmo S, Reseland JE, et al. Increased circulating hepatocyte growth factor (HGF): a marker of epithelial ovarian cancer and an indicator of poor prognosis. Gynecol Oncol 2011;121:402-6.
16. Miyata Y, Kanetake H, Kanda S. Presence of phosphorylated hepatocyte growth factor receptor/c-MET is associated with tumor progression and survival in patients with conventional renal cell carcinoma. Clin Cancer Res 2006;12:4876-81.
17. Greenall SA, Gherardi E, Liu Z, Donoghue JF, Vitali AA, Li Q, et al. Nonagonistic bivalent antibodies that promote c-MET degradation and inhibit tumor growth and others specific for tumor related c-MET. PLoS One 2012;7:e34658.
18. Schoffski P, Garcia JA, Stadler WM, Thierry G, Jonasch E, Tagawa ST, et al. A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma. BJU Int 2010;108:679-86.
19. Tiran Z, Oren A, Hermesh C, Rotman G, Levine Z, Amitai H, et al.Anovel recombinant soluble splice variant of MET is a potent antagonist of the hepatocyte growth factor/scatter factor-MET pathway. Clin Cancer Res 2008;14:4612-21.
20. Coxon A, Rex K, Meyer S, Sun J, Sun J, Chen Q, et al. Soluble c-MET receptors inhibit phosphorylation of c-MET and growth of hepatocyte growth factor: c-MET-dependent tumors in animal models. Mol Cancer Ther 2009;8:1119-25.
21. Cecchi F, Rabe DC, Bottaro DP. Targeting the HGF/MET signaling pathway in cancer therapy. Expert Opin Ther Targets 2012;16:553-72.
22. Sattler M, Salgia R. c-MET and hepatocyte growth factor: potential as novel targets in cancer therapy. Cur Oncol Rep 2007;9:102-8.
23. Merchant M, Ma X, Maun HR, Zheng Z, Peng J, Romero M, et al. Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent. Proc Natl Acad Sci USA 2013;110:E2987-96.
24. Martens T, Schmidt NO, Eckerich C, Fillbrandt R, Merchant M, Schwall R, et al. A novel one-armed anti-c-MET antibody inhibits glioblastoma growth in vivo. Clin Cancer Res 2006;12:6144-52.
25. Jin H, Yang R, Zheng Z, Romero M, Ross J, Bou-Reslan H, et al. Onartuzumab, the one-armed 5D5 anti-c-MET antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Res 2008;68:4360-8.
26. Surati M, Patel P, Peterson A, Salgia R. Role of MetMAb (OA-5D5) in c-MET active lung malignancies. Expert Opin Biol Ther 2011;11: 1655-62.
27. Spigel DR, Ervin TJ, Ramlau RA, Daniel DB, Goldschmidt JH, Blumenschein GR, et al. Randomized phase II trial of onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol 2013;31:4105-14.
28. Nath D, Williamson NJ, Jarvis R, Murphy G. Shedding of c-MET is regulated by crosstalk between a G-protein coupled receptor and the EGF receptor and is mediated by a TIMP-3 sensitive metalloproteinase. J Cell Sci 2001;114:1213-20.
29. Xiang H, Bender BC, Reyes AE 2nd, Merchant M, Jumbe NL, Romero M, et al. Onartuzumab (MetMAb): using nonclinical pharmacokinetic and concentration-effect data to support clinical development. Clin Cancer Res 2013;19:5066-78.
30. Ancot F, Leroy C, Ghaffar G, Lefebvre J, Vicogne J, Lemiere A, et al. Shedding-generated Met receptor fragments can be routed to either the proteasomal or the lysosomal degradation pathway. Traffic 2012; 13:1261-72.
31. Schelter F, Kobuch J, Moss ML, Becherer JD, Comoglio PM, Boccaccio C, et al. A disintegrin and metalloproteinase-10 (ADAM-10) mediates DN-30 antibody-induced shedding of the MET surface receptor. J Biol Chem 2010;285:26335-40.
32. Wajih N, Walter J, Sane DC. Vascular origin of a soluble truncated form of the hepaptocyte growth factor receptor (c-MET). Circ Res 2002; 90:46-52.
33. Wader KF, Fagerli UM, Holt RU, Borset M, Sundan A, Waage A. Soluble c-met in serum of patients with multiple myeloma: correlation with clinical parameters. Eur J Haematol 2011;87:394-9.
34. Prat M, Crepaldi T, Gandino L, Giordano S, Longati P, Comoglio P. Cterminal truncated forms of Met, the hepatocyte growth factor receptor. Mol Cell Biol 1991;11:5954-62.
35. Dharmawardana PG, Coleman JA, Wimberly J, Giubellino A, Sun J, Burgess TL, et al. Soluble c-MET ectodomain detection in urologic malignancies. Proc Am Assoc Cancer Res 2005;46:Abstract 2788.
36. Athauda G, Giubellino A, Coleman JA, Horak C, Steeg PS, Lee MJ, et al. c-MET ectodomain shedding rate correlates with malignant potential. Clin Cancer Res 2006;12:4154-62.
37. Shah MA, Wainberg ZA, Catenacci DV, Hochster HS, Ford J, Kunz P, et al. Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor in patients with metastatic gastric cancer. PLoS One 2013;8:e54014.
38. Pozner-Moulis S, Pappas DJ, Rimm D. MET, the hepatocyte growth factor receptor, localizes to the nucleus in cells at low density. Cancer Res 2006;66:7976-82.
39. Petrelli A, Circosta P, Granziero L, Mazzone M, Pisacane A, Fenoglio S, et al. Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity. Proc Nat Acad Sci 2006;103:5090-5.
40. Gray DC, Hoeflich KP, Peng L, Gu Z, Gogineni A, Murray LJ, et al. pHUSH: a single vector system for conditional gene expression. BMC Biotechnol 2007;26:61.
41. Hoeflich KP, Gray DC, Eby MT, Tien JY, Wong L, Bower J, et al. Oncogenic BRAF is required for tumor growth and maintenance in melanoma models. Cancer Res 2006;15:999-1006.
42. Sakon M, Kita Y, Takeda Y, Higaki N, Ohzato H, Umeshita K, et al. Measurement of hepatocyte growth factor in serum and plasma. Int J Clin Lab Res 1999;29:110-3.
43. McDermott U, Sharma SV, Dowell L, Greninger P,Montagut C, Lamb J, et al. Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci USA 2007;104:19936-41.
44. Fu L, Guo W, Liu B, Sun L, Bi Z, Zhu L, et al. Shedding of c-Met ectodomain correlates with c-Met expression in non-small cell lung cancer. Biomarkers 2013;18:126-35.
45. Yang Y, Wang Y, Zeng X, Ma XJ, Zhao Y, Qiao J, et al. Self-control of HGF regulation on human trophoblast cell invasion via enhancing c- Met receptor shedding by ADAM10 and ADAM17. J Clin Endocrinol Metab 2012;97:E1390-401.
46. Penuel E, Li C, Parab V, Burton L, Cowan KJ, Merchant M, et al. HGF as a circulating biomarker of onartuzumab treatment in patients with advanced solid tumors. Mol Cancer Ther 2013;12: 1122-30.
47. Bai S, Xin Y, Jin D, Kaur S, Nijem I, Bothos JG, et al. Population pharmacokinetic analysis from phase I and phase II studies of the humanized monovalent antibody, MetMAb, in patients with advanced solid tumors. J Clin Oncol 2011;29(Suppl.): Abstract 2571.
48. Choi JS, Kim MK, Seo JW, Choi YL, Kim DH, Chun YK, et al. MET expression in sporadic renal cell carcinomas. J Korean Med Sci 2006;21:672-7.
49. Ginty F, Adak S, Can A, Gerdes M, Larsen M, Cline H, et al. The relative distribution of membranous and cytoplasmic MET is a prognostic indicator in stage I and II colon cancer. Clin Cancer Res 2008;14: 3814-22.
50. Pugliese M, Stempel M, Patil S, Hsu M, Ho A, Traina T, et al. The clinical impact and outcomes of immunohistochemistry-only metastasis in breast cancer. Am J Surg 2010;200:368-73.